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Migraine headaches impart substantial personal
and ﬁnancial costs on individuals, health systems,
and employers. We have known for nearly two dec-
ades that one-tenth or more of the population suf-
fers from migraines in a given year [1]. For persons
experiencing migraines, multiple episodes consume
an average of more than 2 weeks per year [2]. For
health systems, persons with migraines use signiﬁ-
cantly more physician services and pharmaceutical
services than persons without migraines. For
employers, missed days of work, or absenteeism,
and reduced productivity at work, presenteeism,
cost one-half percent of total labor productivity, a
ﬁgure that translates to one-tenth of net corporate
proﬁts in 2000. Clearly, the appropriate treatment
of migraines is a substantial societal concern.
With the introduction of selective serotonin
receptor agonists (triptans), pharmaceutical treat-
ment has more effectively addressed the burden of
migraines. Studies of triptans have demonstrated
their ability to reduce the duration of migraines
and, in some cases, reduce other medical costs and
time lost from work. Among the questions facing
pharmaceutical beneﬁt decision makers are, should
triptans be included on preferred drug lists, such
as formularies, subsidy schedules, etc., and if so,
which ones? Decision makers are obviously con-
cerned with the effectiveness of each migraine med-
ication. So too are they increasingly concerned with
its cost and cost-effectiveness. The use of particular
measures of effectiveness and costs may vary with
the role of the decision maker, pharmacy beneﬁt
manager, health plan manager, employer, etc., and
the relative weight the decision maker places on
effectiveness of treatment and a line item in a
budget.
In the case of migraines, the standard measure of
effectiveness has been improvement at 2 hours.
Improvement is typically measured as moving from
some patient-reported level of pain to a lower level
of pain. Recent investigations have pushed the
measures of effectiveness to more precisely address
the complaints of migraine sufferers. A contribution
made by Wells et al. [3] in this issue of Value in
Health is the use of two measures of treatment
effectiveness that go beyond improvement at 2
hours. Speciﬁcally, they compare eletriptan and
sumatriptan using 1) pain-free, not just improve-
ment, at 2 hours, with no recurrence within
24 hours of the ﬁrst dosing and no requirement for
rescue medication, and 2) improvement at 1 hour,
followed by pain-free status at 2 hours and sus-
tained at 4 hours and the absence of recurrence
within 24 hours of the ﬁrst dosing.
The differences in the percentage of patients suc-
cessfully treated with eletriptan and sumatriptan
diminishes as increasingly stringent measures are
evaluated, from 64% to 67% versus 50% to 53%
for improvement at 2 hours to 16% to 17% versus
14% to 16% for improvement at 1 hour for elet-
riptan and sumatriptan, respectively. Since the data
for this study were not generated for the purpose of
the speciﬁc analyses conducted, the statistical signif-
icance of certain comparisons is modest, but do not
qualitatively affect results. Findings are similar to a
comparison among other triptans with alternative
effectiveness measures that are also more stringent
than improvement at 2 hours [4].
The two additional effectiveness measures more
clearly deﬁne patients concerns with migraines. The
results also suggest three avenues for future
research. First, the added measures address areas of
concern to patients, but the relative importance of
such concerns, improvement at 2 hours versus pain-
free at 1 hour, has yet to be measured. As an ulti-
mate measure of patient well-being, a quality-of-life
measure transformed into quality-adjusted life-
years (QALYs) might be appropriate. There are
available quality-of-life measures speciﬁcally
applied to migraine that could be used to address
the added value of more detailed effectiveness meas-
ures [5]. Further, standardizing outcomes into
QALYs would permit comparisons across illnesses.
Decision makers are required to make trade-offs
among illnesses demanding scare resources.
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Second, the relative effectiveness of treatments
among subpopulations has yet to be addressed. In
the determination of differences in effectiveness
between eletriptan and sumatriptan, logistic regres-
sions were performed with treatment as the only
regressor. Age and gender were similar between the
two groups of patients, which was taken as an indi-
cator that the randomization procedure worked
appropriately and that these variables could be sub-
sequently ignored. The later indication may not be
appropriate. It is possible that one medication is
more effective for one particular subgroup, with less
than half of the patients, and still the average would
favor the other medication. Future analyses should
include independent variables such as age, gender,
and comorbidities and speciﬁcally look for subpop-
ulation effects.
Third, the relevance to the employer of alterna-
tive measures of effectiveness merits attention. Log-
ically, there should be correlations among patient-
reported effectiveness measures and time lost from
work, which constitutes two-thirds of total
migraine costs. One study in a managed care setting
found that improvement at 2 hours with a triptan
was associated with a two-thirds reduction in
migraine-related absenteeism, but a minimal change
in presenteeism [6]. Another managed-care organi-
zation found that productivity beneﬁts exceeded
triptan costs by 10-fold [7]. An interesting question
remains unanswered: what is the gain to the
employer from improvement at 1 hour or improve-
ment to pain-free? A quick response might further
reduce absenteeism, address presenteeism, and
make migraine treatment a priority for workplace
wellness programs.
A second contribution made by this study is the
evaluation of cost-effectiveness of treatment. The
study takes a health-care system perspective on
costs—but only includes drug costs. There is an
expectation that other medical services costs would
be proportional to drug costs and future research
should consider total medical cost, including physi-
cian services costs and costs associated with adverse
events. Such research would be particularly useful
to pharmacy beneﬁt managers and health plans.
Cost-effectiveness analysis permits decision makers
to go beyond consideration of only unit costs of
medications.
The preferred drug lists of many entities include
multiple drugs in a single class. In part, inclusion of
multiple drugs reﬂects suspected or veriﬁed differ-
ences in effectiveness of drugs among subgroups of
patients. An analysis of migraine trials recom-
mended that almotriptan, eletriptan, and rizatriptan
be included on preferred drugs lists, each addressing
a speciﬁc concern [8]. Inclusion of multiple drugs
also reﬂects lack of sound evidence for the selection
of a single drug or subset of drugs. Improvements
and perhaps narrowing of preferred drugs lists is
possible through research such as what we see for
migraines. Truly preferred drugs lists will come
about though a process of reﬁning effectiveness
measures to reﬂect what is important to patients
and decision makers, presenting head-to-head trials
and including evidence of cost, effectiveness, and
cost-effectiveness.
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